Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide efficacy trial in Guangxi adults with MASLD and obesity
ChiCTR2600134818Phase 4Not yet recruiting
- Sponsor
- Fourth Affiliated Hospital of Guangxi Medical University
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of tirzepatide in metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity (2 arms), sponsored by Fourth Affiliated Hospital of Guangxi Medical University. Primary endpoint: Liver controlled attenuation parameter at 48 weeks. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesity
Beyond the preview
Go deeper on ChiCTR2600134818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134818.